Filing Flows › Veracyte (VCYT) › Guidance & outlook

Veracyte (VCYT) guidance and outlook

Veracyte (VCYT) lowered its guidance on Nov 4, 2026: Revenue $590M–$593M for FY2026; Revenue +14% to +15% for FY2026; EBITDA margin 26% for FY2026. Veracyte's 10-Q filed Nov 5, 2026 makes 17 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 4, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 5, 2026

• We intend to continue to monitor macroeconomic conditions closely and may determine to take certain financial or operational actions in response to such conditions as appropriate.
• We expect our revenue growth to increase if more payers make a positive coverage decision and as payers enter into contracts with us, which should enhance our revenue and cash collections.
• We expect to continue to see pressure from payers to limit the utilization of tests, generally, and we believe more payers are deploying cost containment tactics, such as requiring prior authorization, reduction of the payer portion of reimbursement and employing laboratory benefit managers to reduce utilization rates.
• We cannot provide any assurance as to when, if ever, or to what extent, any of these amounts will be collected.
• Revenue may not be equal to the billed amount due to a number of factors that we consider when determining revenue accrual rates, including differences in reimbursement rates, the amounts of patient co-payments and co-insurance, the existence of secondary payers, claims denials and the amount we expect to ultimately collect.
• Finally, when we increase our list price, it will increase the cumulative amounts billed but not positively impact accrued revenue.
• We recognize product revenue when control of the promised goods is transferred to our customers, in an amount that reflects the consideration expected to be received in exchange for those products.
• We expect cost of testing revenue in absolute dollars to increase as the number of tests we perform increases.
• However, we expect that the cost per test will decrease over time due to leveraging fixed costs, efficiencies we may gain as test volume increases and process enhancements such as automation, implementation of new technologies and other cost reductions.
• As we introduce new tests, initially our cost per test will be high as we expect to run suboptimal batch sizes, quality control batches, test batches, registry samples, and generally incur costs that may suppress or reduce gross margins.
• As our Prosigna test kits are sold in various configurations with different numbers of tests, our product cost per test will continue to vary based on the specific kit configuration purchased by customers.
• Going forward, we expect to incur significant expense as we invest in the continued development of our innovation engine.

Veracyte's latest quarter

Questions

Did Veracyte raise or lower its guidance?

Veracyte (VCYT) lowered its guidance on Nov 4, 2026: Revenue $590M–$593M for FY2026; Revenue +14% to +15% for FY2026; EBITDA margin 26% for FY2026.

What does Veracyte expect?

We intend to continue to monitor macroeconomic conditions closely and may determine to take certain financial or operational actions in response to such conditions as appropriate. We expect our revenue growth to increase if more payers make a positive coverage decision and as payers enter into contracts with us, which should enhance our revenue and cash collections. We expect to continue to see pressure from payers to limit the utilization of tests, generally, and we believe more payers are deploying cost containment tactics, such as requiring prior authorization, reduction of the payer portio

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.